{"slug":"ceva","name":"Ceva","url":"https://www.gp-intel.com/company/ceva","sector":"Pharma","country":"France","hq_city":null,"website":"https://www.ceva-santeanimale.fr","founded_year":null,"ipo_year":null,"status":"pe_owned","current_owner":"Sagard","current_holder":{"name":"Societe Generale Capital Partenaires, Irdi Capital-Investissement and 6 others","names":["Societe Generale Capital Partenaires","Irdi Capital-Investissement","NiXEN","Merieux Equity Partners","ARCHIMED","EMZ Partners","Grand Sud-Ouest Capital","Sagard"],"since_year":2025,"basis":"active_investor"},"ownership_periods":16,"ownership":[{"owner":"Irdi Capital-Investissement","fund":"IRDI Capital Croissance","fund_vintage":1996,"entry_year":1999,"exit_year":2014,"is_exit":true,"deal_type":"Secondary","buyer":"Grand Sud-Ouest Capital","moic":null,"sector":"Pharma"},{"owner":"PAI Partners","fund":"PAI LBO Fund","fund_vintage":1998,"entry_year":1999,"exit_year":2003,"is_exit":true,"deal_type":"Secondary","buyer":"Industri Kapital","moic":null,"sector":"Pharma"},{"owner":"EMZ Partners","fund":"EMZ Legacy","fund_vintage":2005,"entry_year":1999,"exit_year":2014,"is_exit":true,"deal_type":"Secondary","buyer":"Ceva management with financial investors including Temasek and CDH Investments","moic":null,"sector":"Pharma"},{"owner":"IK Partners","fund":"IK 2000","fund_vintage":2000,"entry_year":2003,"exit_year":2007,"is_exit":true,"deal_type":"MBO","buyer":"Management + Euromezzanine + Natexis","moic":null,"sector":"Pharma"},{"owner":"NiXEN","fund":"NiXEN I","fund_vintage":2005,"entry_year":2007,"exit_year":2014,"is_exit":true,"deal_type":"Secondary","buyer":"Management and employees with Temasek and CDH Investments","moic":null,"sector":"Pharma"},{"owner":"Sagard","fund":"Sagard","fund_vintage":2002,"entry_year":2010,"exit_year":null,"is_exit":false,"deal_type":null,"buyer":null,"moic":null,"sector":"Pharma"},{"owner":"Aquiti Gestion","fund":"NACI 1","fund_vintage":2018,"entry_year":2010,"exit_year":2014,"is_exit":true,"deal_type":"MBO","buyer":"Ceva management and employees with Temasek and CDH Investments","moic":null,"sector":"Pharma"},{"owner":"Grand Sud-Ouest Capital","fund":"Grand Sud Ouest Capital","fund_vintage":1991,"entry_year":2014,"exit_year":2014,"is_exit":false,"deal_type":null,"buyer":null,"moic":null,"sector":"Pharma"},{"owner":"EMZ Partners","fund":"EMZ 9","fund_vintage":2020,"entry_year":2020,"exit_year":2014,"is_exit":false,"deal_type":null,"buyer":null,"moic":null,"sector":"Pharma"},{"owner":"CIC Private Debt","fund":"CIC Debt Fund 4","fund_vintage":2022,"entry_year":2022,"exit_year":2014,"is_exit":false,"deal_type":null,"buyer":null,"moic":null,"sector":"Pharma"},{"owner":"Societe Generale Capital Partenaires","fund":"SGCP Evergreen (balance sheet)","fund_vintage":1991,"entry_year":2025,"exit_year":null,"is_exit":false,"deal_type":null,"buyer":null,"moic":null,"sector":"Pharma"},{"owner":"Irdi Capital-Investissement","fund":"IRDI Capital Croissance","fund_vintage":1996,"entry_year":2025,"exit_year":2014,"is_exit":false,"deal_type":null,"buyer":null,"moic":null,"sector":"Pharma"},{"owner":"NiXEN","fund":"NiXEN II","fund_vintage":2012,"entry_year":2025,"exit_year":null,"is_exit":false,"deal_type":null,"buyer":null,"moic":null,"sector":"Pharma"},{"owner":"Merieux Equity Partners","fund":"Mérieux Participations 4","fund_vintage":2023,"entry_year":2025,"exit_year":null,"is_exit":false,"deal_type":null,"buyer":null,"moic":null,"sector":"Pharma"},{"owner":"ARCHIMED","fund":"MED Rise","fund_vintage":2024,"entry_year":2025,"exit_year":null,"is_exit":false,"deal_type":null,"buyer":null,"moic":null,"sector":"Pharma"},{"owner":"iXO Private Equity","fund":"IXO 3","fund_vintage":2015,"entry_year":null,"exit_year":2025,"is_exit":true,"deal_type":"Secondary","buyer":"ARCHIMED and Institut Mérieux","moic":null,"sector":"Pharma"}],"source":"gp-intel.com","license":"CC-BY-4.0","updated_at":"2026-09-30T09:11:37.218Z"}